Injectable Rifampin Recalled Due to Failed Quality Specifications
Mylan Pharmaceuticals is recalling injectable Rifampin vials nationwide due to failed impurities and degradation specifications discovered during stability testing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves an injectable pharmaceutical with failed quality specifications—impurity and degradation product levels exceeding established standards. No illnesses or hospitalizations have been reported, making this a risk-of-harm product where injury has not yet been documented.
Plain-English summary
Mylan Pharmaceuticals Inc is recalling Rifampin for Injection, USP (600 mg/vial) nationwide. The recall affects 33,893 vials due to failed impurities and degradation specifications.
During stability testing, Mylan found that related compounds in the affected lots were present at levels exceeding the established specifications. This failure means the product may not meet required quality standards.
The recall includes four specific lot numbers with varying expiration dates between December 2022 and April 2023. Patients receiving Rifampin from these lots may be affected.
Healthcare providers and patients should verify the lot number on their medication. If you have received Rifampin from one of the affected lots, contact your healthcare provider or pharmacist for guidance. Do not use recalled product and return it to the pharmacy for proper disposal.
The recalled product
- Product
- RIFAMPIN (RIFAMPIN)
- Brand
- RIFAMPIN
- Manufacturer
- Mylan Pharmaceuticals Inc
- Category
- Drug — Injectable Antibiotic
- Affected units
- 33,893
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #: 7008990
- exp. date Dec-2022
- 7009025
- exp. date Feb-2023
- 7009085
- 7009086
- exp. date Apr-2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · RIFAMPIN
- HighRifampin Antibiotic Capsules Recalled for Subpotency and Failed Specifications
FDA (Drugs) · 2024-02-07
- HighAntibiotic Rifampin Capsules Recalled for Subpotency and Quality Failures
FDA (Drugs) · 2024-02-07
- HighRifampin Capsules Recalled Due to Failed Impurity and Degradation Specification
FDA (Drugs) · 2024-02-07
- HighPrescription Rifampin Capsules Recalled Due to Failed Quality Specifications
FDA (Drugs) · 2023-01-25
- HighPrescription Rifampin Capsules Recalled for Failed Impurity Specifications
FDA (Drugs) · 2023-01-18
Same manufacturer · Mylan Pharmaceuticals Inc
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighPrasugrel 5 mg Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-03-26
- CriticalInsulin Glargine Prefilled Pens Recalled for Missing Label
FDA (Drugs) · 2022-08-03
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17